瑞典3D生物生产商提供商Cellink已发布了与法国再生医学研发公司建立合作伙伴关系的详细信息CTI BIOTECH.
A fully licensed human tissue biobank, CTI BIOTECH is using CELLINK 3D bioprinters to create tumorous tissue models in-lab, and investigate new therapies for patients with cancer.
Professor Colin McGuckin, Founder of CTI BIOTECH, said, “We are proud to partner with CELLINK to advance our 3D Printing technologies in cancer personalized medicine.”
CTI Biotech研究中使用的Bio X 3D Bioprointer游览。剪辑通过CELLINK 3Don YouTube.
Understanding cancer on a cellular level
It has been almost a year since CELLINK announced the launch of its最新的3D生物生产商 - Bio X. Now installed in CTI BIOTECH’s lab, the BIO X will work with cells extracted from tissue samples of cancer patients tumors.
与支持材料相结合，即水凝胶，这些细胞将被打印到活副本肿瘤中，可用于测试对新疗法的反应。
It is hoped that the models will be able to reduce the costly 40%+ attrition rate of pre-clinical drug screenings. According to Professor McGuckin, “Cancer therapies have been severely limited by our understanding of how the cancer grows in 3D tumors.”
3D bioprinting and cancer
许多国际研究机构，包括Indian Institute of Technology Hyderabad和Ku Leuvenhave been评估癌症研究的3D生物打印值最近几年。
The Wake Forest Institute for Regenerative Medicine (WFIRM) is using itsbody-on-a-chip deviceto test new drugs for the disease, and evenNASA has taken 3D bioprinters in space测试癌组织模型的制造。
更好地治疗不可预测的疾病
Erik Gatenholm, co-founder and CEO of CELLINK comments, “We are always excited when our technologies are used to accelerate research and enable new advancements,”
“肿瘤研究领域是我们的主要重点领域之一，我们看到使用我们的生物打印平台来开发更好，更现实的癌症组织模型的强大好处，以便我们可以开发更好的治疗方法。”
2017年11月，Cellink还从欧盟Horizon 2020倡议中获得了350,000欧元（417,889美元）。Cellink将与其他5个合作伙伴一起，将在Silkfusion项目中致力于基因工程的血小板，以进行“输血和药物研究”。
Stay up to date with all the latest 3D bioprinting developments at3D Printing Industry on Twitter和Facebook.Subscribe to our regular newsletter here.
这项研究或涉及的团队是否引起了您的注意？确保他们在第二个年度3D印刷行业中得到认可在这里提名他们。
Featured image shows a sample 3D bioprinted ear model. Photo via CELLINK
